高倩,郎晓琴,何菊英

• 1:陆军军医大学第一附属医院药学部

摘要(Abstract)：

报道1例肝胆管结石伴慢性胆管炎患者术后产金属β-内酰胺酶（MBL）多重耐药革兰阴性杆菌引起复杂腹腔感染的病例。临床药师结合患者病情，通过解读药敏报告、监测血药浓度及处理抗菌药物不良反应等措施，为患者制定个体化抗感染方案并提供全程的药学监护，患者感染得到有效控制并取得了良好的治疗效果。

关键词(KeyWords)： 金属β内酰胺酶;多重耐药;复杂腹腔感染;药学实践

Abstract:

Keywords:

基金项目(Foundation): 重庆市临床药学重点专科建设项目（编号425Z2M2）

作者(Author): 高倩,郎晓琴,何菊英

DOI: 10.19577/j.1007-4406.2023.05.012

参考文献(References)：

• [1]胡必杰.中国碳青霉烯耐药革兰阴性杆菌(CRO)感染预防与控制技术指引[J].中华医院感染学杂志, 2019, 29(13):2075.
• [2]全国细菌耐药监测网. 2021年全国细菌耐药监测报告（简要版）[EB/OL].(2023-01-10).http://www.carss.cn/Report/Details/862.
• [3] HAN R R, SHI Q Y, WU S, et al. Dissemination of carbapenemases(KPC, NDM, OXA-48, IMP, and VIM)among carbapenemresistant Enterobacteriaceae isolated from adult and children patients in China[J]. Front Cell Infect Microbiol, 2020, 10:314.
• [4]中华医学会外科学分会胆道外科学组．急性胆道系统感染的诊断和治疗指南（2021版）[J]．中华外科杂志，2021,59(6):422.
• [5]《抗菌药物临床应用指导原则》修订工作组.抗菌药物临床应用指导原则（2015年版）[M].北京:人民卫生出版社, 2015.
• [6] SY C L, CHEN P Y, CHENG C W, et al. Recommendations and guidelines for the treatment of infections due to multidrug resistant organisms[J]. J Microbiol Immunol Infect, 2022, 55(3):359.
• [7] PINTADO V, RUIZ-GARBAJOSA P, AGUILERA-ALONSO D, et al. Executive summary of the consensus document of the Spanish Society of Infectious Diseases and Clinical Microbiology(SEIMC)on the diagnosis and antimicrobial treatment of infections due to carbapenem-resistant gram-negative bacteria[J]. Enferm Infecc Microbiol Clin, 2023, 41(6):360.
• [8] ZENG M, XIA J, ZONG Z Y, et al. Guidelines for the diagnosis,t r e a t m e n t, p r e v e n t i o n a n d c o n t r o l o f i n f e c t i o n s c a u s e d b y carbapenem-resistant gram-negative bacilli[J]. J Microbiol Immunol Infect, 2023:S1684.
• [9] EL-SAYED AHMED M A E, ZHONG L L, SHEN C, et al. Colistin and its role in the Era of antibiotic resistance:an extended review(2000-2019)[J]. Emerg Microbes Infect, 2020, 9(1):868.
• [10]中国医药教育协会感染疾病专业委员会,中华医学会呼吸病学分会,中华医学会重症医学分会,等.中国多黏菌素类抗菌药物临床合理应用多学科专家共识[J].中华结核和呼吸杂志, 2021,44(4):292.
• [11] KIM E J, OH J, LEE K, et al. Pharmacokinetic characteristics and limited sampling strategies for therapeutic drug monitoring of colistin in patients with multidrug-resistant gram-negative bacterial infections[J]. Ther Drug Monit, 2019, 41(1):102.
• [12] WANG P L, ZHANG Q W, ZHU Z F, et al. Population pharmacokinetics and limited sampling strategy for therapeutic drug monitoring of polymyxin B in Chinese patients with multidrug-resistant gram-negative bacterial infections[J]. Front Pharmacol, 2020, 11:829.
• [13]郑飞跃,吴燕,饶跃峰,等.诺氏评估量表在药物不良反应评价中的作用及实例分析[J].中国药学杂志, 2012, 47(8):650.
• [14]赵苗,张菁,张婴元.多黏菌素临床药理学研究新进展[J].中国感染与化疗杂志, 2012, 12(6):466.
• [15] XU Y, LIANG P, LIU N, et al. Correlation between the drug concentration of polymyxin B and polymyxin B-associated acute kidney injury in critically ill patients:a prospective study[J].Pharmacol Res Perspect, 2022, 10(5):e01010.
• [16] NATION R L, RIGATTO M H P, FALCI D R, et al. Polymyxin acute kidney injury:dosing and other strategies to reduce toxicity[J]. Antibiotics, 2019, 8(1):24.
• [17] LIU X F, CHEN Y C, YANG H J, et al. Acute toxicity is a dose-limiting factor for intravenous polymyxin B:a safety and pharmacokinetic study in healthy Chinese subjects[J]. J Infect,2021, 82(2):207.
• [18] RADY O M S M, EL-ATTAR L, AMINE A. In vitro synergistic activity of colistin and teicoplanin combination against multidrugresistant Acinetobacter spp[J]. J Antibiot, 2022, 75(3):181.
• [19] BAE S, KIM M C, PARK S J, et al. In vitro synergistic activity of antimicrobial agents in combination against clinical isolates of colistin-resistant acinetobacter baumannii[J]. Antimicrob Agents Chemother, 2016, 60(11):6774.
• [20] CIRIONI O, SIMONETTI O, PIERPAOLI E, et al. Colistin enhances therapeutic efficacy of daptomycin or teicoplanin in a murine model of multiresistant Acinetobacter baumannii sepsis[J].Diagn Microbiol Infect Dis, 2016, 86(4):392.
• [21] BIAN X C, LIU X F, HU F P, et al. Pharmacokinetic/p h a r m a c o d y n a m i c b a s e d b r e a k p o i n t s o f p o l y m y x i n B f o r bloodstream infections caused by multidrug-resistant gramnegative pathogens[J]. Front Pharmacol, 2021, 12:785893.